Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

877 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW. Lübbert M, et al. Among authors: ganser a. J Clin Oncol. 2011 May 20;29(15):1987-96. doi: 10.1200/JCO.2010.30.9245. Epub 2011 Apr 11. J Clin Oncol. 2011. PMID: 21483003 Clinical Trial.
Biologic effects of recombinant human interleukin-3 in vivo.
Lindemann A, Ganser A, Herrmann F, Frisch J, Seipelt G, Schulz G, Hoelzer D, Mertelsmann R. Lindemann A, et al. Among authors: ganser a. J Clin Oncol. 1991 Dec;9(12):2120-7. doi: 10.1200/JCO.1991.9.12.2120. J Clin Oncol. 1991. PMID: 1960553 Clinical Trial.
Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells.
Aivado M, Rong A, Stadler M, Germing U, Giagounidis A, Strupp C, Novotny J, Josten KM, Kobbe G, Hildebrandt B, Gattermann N, Aul C, Haas R, Ganser A. Aivado M, et al. Among authors: ganser a. Eur J Haematol. 2002 Apr;68(4):210-6. doi: 10.1034/j.1600-0609.2002.01625.x. Eur J Haematol. 2002. PMID: 12071936 Clinical Trial.
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.
Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK, Schrezenmeier H, Novotny J, Anders O, Eimermacher H, Verbeek W, Kreipe HH, Heimpel H, Aul C, Ganser A. Stadler M, et al. Among authors: ganser a. Leukemia. 2004 Mar;18(3):460-5. doi: 10.1038/sj.leu.2403239. Leukemia. 2004. PMID: 14712285 Clinical Trial.
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.
Schlenk RF, Benner A, Krauter J, Büchner T, Sauerland C, Ehninger G, Schaich M, Mohr B, Niederwieser D, Krahl R, Pasold R, Döhner K, Ganser A, Döhner H, Heil G. Schlenk RF, et al. Among authors: ganser a. J Clin Oncol. 2004 Sep 15;22(18):3741-50. doi: 10.1200/JCO.2004.03.012. Epub 2004 Aug 2. J Clin Oncol. 2004. PMID: 15289486
Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study.
Giagounidis AA, Haase S, Germing U, Schlegelberger B, Wilkens L, Büsche G, Kreipe HH, Wysk J, Grips KH, Grabenhorst U, Rothmann F, Lübbert M, Ganser A, Aivado M, Heinsch M, Aul C. Giagounidis AA, et al. Among authors: ganser a. Ann Hematol. 2005 Jun;84(6):389-94. doi: 10.1007/s00277-005-1027-3. Epub 2005 Mar 23. Ann Hematol. 2005. PMID: 15785949 Clinical Trial.
877 results